Literature DB >> 11155197

Case studies in heparin-induced thrombocytopenia.

A C Andreescu1, M Cushman.   

Abstract

Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications. Here, we present illustrative case histories to educate the reader on evaluation and management of this complex syndrome. Cases include typical and unusual presentations of the syndrome, and commonly encountered problems and pitfalls of therapy. Major points illustrated are, (1) occurrence of HIT with any dose or form of heparin; (2) misperceptions on the diagnostic criteria; (3) correct (thrombin inhibitors) and incorrect (platelet transfusions and warfarin) management; (4) influence of management strategy on clinical outcomes; (5) severity of the syndrome; and (6) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time. Effective therapy of HIT involves both the prompt recognition of the syndrome and its proper management.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11155197     DOI: 10.1023/a:1027341521840

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  17 in total

Review 1.  College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.

Authors:  M Laposata; D Green; E M Van Cott; T W Barrowcliffe; S H Goodnight; R C Sosolik
Journal:  Arch Pathol Lab Med       Date:  1998-09       Impact factor: 5.534

2.  Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: a clinician's perspective.

Authors:  D E Wallis; B E Lewis; J M Walenga
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

Review 3.  Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis.

Authors:  A Greinacher
Journal:  Semin Thromb Hemost       Date:  1995       Impact factor: 4.180

4.  Characterization of the humoral immune response in heparin-induced thrombocytopenia.

Authors:  J S Suh; M I Malik; R H Aster; G P Visentin
Journal:  Am J Hematol       Date:  1997-03       Impact factor: 10.047

Review 5.  Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases.

Authors:  V V Kadidal; D J Mayo; M K Horne
Journal:  J Intern Med       Date:  1999-09       Impact factor: 8.989

6.  The mechanism of heparin-induced platelet aggregation.

Authors:  B H Chong; F Ismail
Journal:  Eur J Haematol       Date:  1989-09       Impact factor: 2.997

Review 7.  Heparin-induced thrombocytopenia: a ten-year retrospective.

Authors:  T E Warkentin
Journal:  Annu Rev Med       Date:  1999       Impact factor: 13.739

8.  Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation.

Authors:  B H Chong; W R Pitney; P A Castaldi
Journal:  Lancet       Date:  1982-12-04       Impact factor: 79.321

9.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

10.  Heparin-associated thrombocytopenia (HAT)--still a diagnostic and therapeutical problem in clinical practice.

Authors:  S Kleinschmidt; U T Seyfert
Journal:  Angiology       Date:  1995-01       Impact factor: 3.619

View more
  4 in total

1.  Case studies in anticoagulation management.

Authors:  Wendy A Leong
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

Review 2.  Low molecular weight heparin therapy for percutaneous coronary intervention: a practice in evolution.

Authors:  J K Choo; D J Kereiakes
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

3.  [Sinus vein thrombosis. A rare complication of heparin-induced thrombocytopenia type II].

Authors:  S Merz; R Fehr; C Gülke
Journal:  Anaesthesist       Date:  2004-06       Impact factor: 1.041

4.  Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: an observational retrospective case-control study.

Authors:  Elise M Gettings; Kathryn A Brush; Elizabeth M Van Cott; William E Hurford
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.